Advent International backs NZCR Group
The group's NZCR, CMAX, Optimal and Fusion brands provide integrated Phase I–IV clinical trial capabilities to global pharmaceutical, biotechnology and contract research organization customers.
Advent International acquired a majority stake in NZCR Group, a physician-led clinical trials and medical research organization operating in New Zealand and Australia. The group's NZCR, CMAX, Optimal and Fusion brands provide integrated Phase I–IV clinical trial capabilities to global pharmaceutical, biotechnology and contract research organization customers.
Existing shareholders, including Waterman Capital and clinician shareholders, are retaining a significant minority stake.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.